Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 3c, Slight Miss on Revenues; Updates FY17 Outlook

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $2.31, $0.03 worse than the analyst estimate of $2.34. Revenue for the quarter came in at $376 million versus the consensus estimate of $377.02 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2017 EPS of $10.70-$11.30, versus the consensus of $11.12. Jazz Pharmaceuticals sees FY2017 revenue of $1.625-1.7 billion, versus the consensus of $1.67 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Morgan Stanley upgrades CDW on stronger AI-driven server demand